Trial reportCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2005
Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.
Trial report in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination.AIDS and behavior · 2018Trial
- Trial
- Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2012Trial
- A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.BMC infectious diseases · 2011Trial
- Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.Vaccine · 2014Article
- Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2014Article
- Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.PloS one · 2014Article
- Article
- Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?Vaccine · 2013Article
- Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township.International journal of STD & AIDS · 2012Article
- Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination.Archives of pediatrics & adolescent medicine · 2012Article
- Fishermen as a Suitable Population for HIV Intervention Trials.AIDS research and treatment · 2010Article
- Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.Journal of acquired immune deficiency syndromes (1999) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhase I and phase II HIV-1 vaccine trials have revealed increases in risky sexual activity among study subjects during the trials, perhaps because the subjects believe that the vaccine being tested is efficacious; subjects may thus suffer harm from their participation. We evaluated the sexual behaviour of Canadian men who have sex with men (MSM) who participated in the phase III Vax004 trial of an HIV-1 vaccine.
methodsUsing self-reports of sexual behaviours during the 6 months before trial entry as a baseline, we determined changes in reported sexual behaviour after 6, 12 and 18 months of participation in the trial.
resultsOf 291 HIV-seronegative MSM enrolled from July to October 1999, 260 (89%) completed 18 months of follow-up, 19 (7%) experienced seroconversion, and 12 (4%) did not complete follow-up. Unprotected receptive anal intercourse during the previous 6 months with partners whose HIV-1 serostatus was positive or unknown was reported by 21% of men at enrollment and by 27% at any point during 18 months of follow-up. No increase in this behaviour from baseline was reported by participants, including among men who were motivated to enroll because of expected protection from HIV-1 infection, men who believed they had received the vaccine, men who believed that the vaccine had greater than 50% efficacy, or men who believed that they had received the vaccine and that vaccine efficacy was greater than 50%.
interpretationMSM can be successfully enrolled in HIV-1 vaccine efficacy trials without evident increases in those sexual behaviours most associated with HIV-1 risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.